Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

tax adjustments primarily related to changes in valuation allowances, the settlement of the investigations by the U.S. Attorney's Office and other changes in tax assets and liabilities. The 2008 amount includes $84.5 million of tax benefits for the settlement with the U.S. Attorney's Office, for which the related expense was recorded in 2007 and for the states of Connecticut and Massachusetts, for which the related expense was recorded in the third quarter of 2008.

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Adjusted Net Income

(Unaudited)

Nine Months Ended

September 30,

2008 2007

GAAP NET (LOSS) INCOME $210,962 $(235,886)

Cost of sales adjustments 111,349 (1) 64,236 (1)

Research and development adjustments 8,013 (2) 41,500 (2)

Selling, general and administrative

adjustments 30,124 (3) -

Settlement reserve 7,450 (4) 425,000 (4)

Gain on sale of investment - (5,791) (5)

Gain on extinguishment of debt - (5,319) (6)

Interest expense adjustment 11,250 (7)

Restructuring charges 6,973 (8)

In-process research and development 10,000 (9)

Income tax adjustment (143,162) (10) (40,459) (10)

41,997 479,167

ADJUSTED NET INCOME $252,959 $243,281

BASIC ADJUSTED INCOME PER COMMON

SHARE $3.73 $3.66

DILUTED ADJUSTED INCOME PER COMMON

SHARE
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... England , May 22, 2013 ... novel drug-only formulation of glycopyrronium bromide designed using Prosonix, ... pharmaceutical company developing a portfolio of inhaled Respiratory ... clinical study with PSX1002 that will assess its effect ... of doses in patients with moderate to severe chronic ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Custom ... to reporting eLearning solution using Tin Can API ... dashboard tool. CLD is a leading developer of ... medical device companies worldwide. , Tin Can ... that helps learners and trainers more accurately measure ...
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
(Date:5/21/2013)... 21, 2013 Clinverse, Inc. ... for clinical trials, announced today it has formed ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates ... SpendMD ™, Aggregate Spend Solutions’ recently-launched ... tracking and reporting transfer of value at investigator ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3
... 29, 2012  Dyadic International, Inc. ("Dyadic") (OTC Pink: ... discovery, development, manufacture and sale of enzyme and ... biopharmaceutical industries, announced today that it has entered ... a leading global provider of nutritional ingredient solutions ...
... the Wyss Institute for Biologically Inspired Engineering at Harvard ... for inducing magnetic sensitivity in an organism that is ... used to magnetize a variety of different cell types ... appear in today,s issue of PLoS Biology . ...
... 28, 2012  Thomson Reuters announced the availability of ... speeds access to critical life sciences research and ... platform, Thomson Reuters Cortellis. ... application programming interfaces (APIs) to enhance the research ...
Cached Biology Technology:Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes 2Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes 3New 'magnetic yeast' marks step toward harnessing Nature's magnetic capabilities 2New 'magnetic yeast' marks step toward harnessing Nature's magnetic capabilities 3Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services 2
(Date:5/22/2013)... engineering drastically reduces the time and effort needed ... of biotechnology, scientists are reporting. Published in the ... paves the way for more rapid development of ... other activities. , Keith Shearwin and colleagues explain ... genetic material DNA into a bacterium,s genome is ...
(Date:5/22/2013)... feared Legionella pneumophila bacteria is responsible for ... In order to infect us, this pathogen has developed ... go unnoticed in our cells, thus avoiding these acting ... Basque biosciences research centre, CIC bioGUNE, in which teams ... USA and the National Supercomputation Centre in Barcelona (BSC) ...
(Date:5/22/2013)... in the biodiversity of pollinating insects and wild plants ... study. , Researchers led by the University of Leeds ... evidence of dramatic reductions in the diversity of ... 1950s and 1980s. , But the picture brightened markedly ... biodiversity losses among bees, hoverflies and wild plants. ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... fragments into a genome sequence that scientists can interpret is ... don,t have the box and have no idea what the ... DNA sequences of related organisms can be used to guide ... related any two sequences are to one another. For example, ...
... Radiology," the first in a series of annual ... invasive medicine, was recently released by Society of ... radiology is expanding, and it has become increasingly ... assimilate the volume of literature required to remain ...
... Scientists at the Salk Institute for Biological Studies and ... that play a role in the production of seed ... chemicals and biofuels. Scoring a rare scientific hat ... thale cress plants ( Arabidopsis thaliana ) that regulate ...
Cached Biology News:Researchers look to relatives for clues in quest to develop sources of bioenergy 2Researchers look to relatives for clues in quest to develop sources of bioenergy 3'Updates in Interventional Radiology' accents emerging trends, practice growth 2Discovery of plant proteins may boost agricultural yields and biofuel production 2Discovery of plant proteins may boost agricultural yields and biofuel production 3
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Biology Products: